Charles River Labs Posts Strong Q2 Growth, Net Income Up 12%

TL;DR

CRL's Q2 numbers are solid, showing strong demand in drug research, so buy the dip if you're looking for a stable growth play.

AI Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported a robust financial performance for the second quarter ended June 28, 2025. Total revenue for the three months ended June 28, 2025, reached $1.32 billion, marking a significant increase from $1.21 billion in the prior-year period. Service revenue contributed $1.15 billion, up from $1.05 billion, while product revenue grew to $170 million from $160 million. Net income for the quarter was $155 million, a healthy rise from $138 million in the same period last year. The company's strategic outlook remains positive, driven by strong demand in its research models and services segments. Key risks include potential fluctuations in R&D spending by pharmaceutical clients and ongoing supply chain challenges, though the current filing indicates effective management of these factors. The company's balance sheet shows total assets of $10.5 billion as of June 28, 2025, compared to $10.2 billion at December 28, 2024, reflecting continued growth and investment.

Why It Matters

This strong Q2 performance by Charles River Laboratories signals robust demand in the drug discovery and development sector, benefiting investors through increased profitability and potential stock appreciation. For employees, it suggests job security and growth opportunities within a thriving company. Customers, primarily pharmaceutical and biotech firms, can expect continued high-quality research support, which is crucial for bringing new therapies to market. In the competitive landscape, CRL's growth reinforces its position as a leading contract research organization, potentially pressuring smaller competitors and attracting further industry consolidation.

Risk Assessment

Risk Level: low — The risk level is low due to consistent revenue growth, with total revenue increasing from $1.21 billion to $1.32 billion year-over-year, and a healthy net income rise from $138 million to $155 million. The company's diversified service and product offerings, coupled with a strong balance sheet showing total assets of $10.5 billion, provide a stable financial foundation.

Analyst Insight

Investors should consider holding or initiating a long position in CRL, given its consistent growth in revenue and net income. The company's strong performance in the essential drug discovery sector suggests continued resilience and market leadership.

Financial Highlights

revenue

$1.32B

total Assets

$10.5B

net Income

$155M

revenue Growth

+9.1%

Revenue Breakdown

Key Numbers

• $1.32B — Total Revenue Q2 2025 (Increased from $1.21B in Q2 2024, showing 9.1% growth.)
• $155M — Net Income Q2 2025 (Increased from $138M in Q2 2024, representing a 12.3% rise.)
• $1.15B — Service Revenue Q2 2025 (Up from $1.05B in Q2 2024, indicating strong demand for services.)
• $170M — Product Revenue Q2 2025 (Increased from $160M in Q2 2024, reflecting product segment growth.)
• $10.5B — Total Assets as of June 28, 2025 (Grew from $10.2B at December 28, 2024, demonstrating balance sheet strength.)

Key Players & Entities

• CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (company) — filer of the 10-Q
• Bloomberg (company) — financial news outlet
• SEC (regulator) — Securities and Exchange Commission
• $1.32 billion (dollar_amount) — total revenue for Q2 2025
• $1.21 billion (dollar_amount) — total revenue for Q2 2024
• $155 million (dollar_amount) — net income for Q2 2025
• $138 million (dollar_amount) — net income for Q2 2024
• $10.5 billion (dollar_amount) — total assets as of June 28, 2025
• $10.2 billion (dollar_amount) — total assets as of December 28, 2024
• Wilmington, MA (location) — company headquarters

FAQ

Industry Context

Charles River Laboratories operates in the commercial physical and biological research sector. The industry is characterized by significant R&D spending from pharmaceutical and biotechnology clients. Key trends include the increasing outsourcing of research and development activities and the growing demand for specialized research models and services.

Regulatory Implications

As a provider of research services, Charles River Laboratories is subject to various regulatory standards and compliance requirements, particularly concerning animal welfare and laboratory practices. Adherence to these regulations is crucial for maintaining operational integrity and client trust.

What Investors Should Do

1. Monitor R&D spending trends of pharmaceutical clients.
2. Assess the company's ability to manage supply chain challenges.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information for Charles River Laboratories International, Inc. for the second quarter of 2025.)

Service Revenue

Revenue generated from providing services, as opposed to selling physical products. (A significant portion of Charles River Laboratories' revenue, indicating strong demand for their research and development services.)

Product Revenue

Revenue generated from the sale of physical goods or products. (Represents the portion of Charles River Laboratories' revenue derived from their product offerings.)

Year-Over-Year Comparison

Total revenue for Q2 2025 increased by 9.1% to $1.32 billion compared to $1.21 billion in the prior-year period. Net income saw a 12.3% rise to $155 million from $138 million. Total assets grew to $10.5 billion from $10.2 billion at the end of the previous fiscal year, indicating continued investment and balance sheet expansion.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR